Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.48 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL88947 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL3838535 | 0.97 | — | — | |
| SCHEMBL14571204 | 0.92 | CRBN (0.52) | OR51E2CRBNFKBP5KDM4EGAA | |
| SCHEMBL20987588 | 0.92 | CRBN (0.52) | OR51E2CRBNFKBP5KDM4EGAA | |
| SCHEMBL25857953 | 0.92 | CRBN (0.52) | OR51E2CRBNFKBP5KDM4EGAA | |
| SCHEMBL23311429 | 0.92 | CRBN (0.52) | OR51E2CRBNFKBP5KDM4EGAA | |
| SCHEMBL10522634 | 0.90 | CXCR4 (0.45) | OR51E2CRBNFKBP5CXCR4SMN1; SMN2 | |
| Azetidine SCHEMBL18173582 | 0.89 | OR51E2 (0.43) | OR51E2CRBNFKBP5CXCR4SMN1; SMN2 | |
| SCHEMBL5194 | 0.82 | — | — | |
| SCHEMBL4393228 | 0.82 | CRBN (0.42) | OR51E2CRBNFKBP5GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744214-B2 | Method of diagnosing and/or monitoring therapy of atherosclerosis | STC.UNM (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190192700-A1 | ANTICANCER THERAPY | STC UNM (US) | 2019-06-27 | — | — | US | disclosed |
| US-10172967-B2 | Anticancer therapy | STC.UNM (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180369430-A1 | METHOD OF DIAGNOSING AND/OR MONITORING THERAPY OF ATHEROSCLEROSIS | UNM RAINFOREST INNOVATIONS | 2018-12-27 | — | — | US | disclosed |
| US-20170304471-A1 | ANTICANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2017-10-26 | — | — | US | disclosed |
| US-9610371-B2 | Anticancer therapy | STC.UNM (US) | 2017-04-04 | — | — | US | disclosed |
| US-9546186-B2 | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma | STC.UNM (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160324993-A1 | NON-INVASIVE DIAGNOSTIC AGENTS OF CANCER AND METHODS OF DIAGNOSING CANCER, ESPECIALLY LEUKEMIA AND LYMPHOMA | STC UNM (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160287728-A1 | NON-INVASIVE DIAGNOSTIC AGENTS AND METHODS OF DIAGNOSING INFECTIOUS DISEASE | STC UNM (US) | 2016-10-06 | — | — | US | disclosed |
| US-9352059-B2 | Non-invasive diagnostic agents and methods of diagnosing infectious disease | STC.UNM (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140086833-A1 | NON-INVASIVE DIAGNOSTIC AGENTS AND METHODS OF DIAGNOSING INFECTIOUS DISEASE | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2014-03-27 | — | — | US | disclosed |
| US-8623322-B2 | Non-invasive diagnostic agents and methods of diagnosing infectious disease | STC.UNM (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130216478-A1 | Non-Invasive Diagnostic Agents of Cancer and Methods of Diagnosing Cancer, Especially Leukemia and Lymphoma | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-08-22 | — | — | US | disclosed |
| US-8435489-B2 | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma | STC.UNM (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120070372-A1 | NON-INVASIVE DIAGNOSTIC AGENTS OF CANCER AND METHODS OF DIAGNOSING CANCER, ESPECIALLY LEUKEMIA AND LYMPHOMA | STC.UNM (US) | 2012-03-22 | — | — | US | disclosed |
| US-8097237-B2 | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma | STC.UNM (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.) | 2011-07-21 | — | — | US | disclosed |
| US-20110117014-A1 | NON-INVASIVE DIAGNOSTIC AGENTS AND METHODS OF DIAGNOSING INFECTIOUS DISEASE | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO C/O RESEARCH & TECHNOLOGY LAW | 2011-05-19 | — | — | US | disclosed |
| US-20070048216-A1 | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-03-01 | — | — | US | disclosed |
| US-20070025910-A1 | Anticancer therapy | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | SLC2A1, SLC2A4, SLC2A3 | OR51E2 3602/4885CRBN 4233/4885FKBP5 4562/4885 |
| US-20120070372-A1 | NON-INVASIVE DIAGNOSTIC AGENTS OF CANCER AND METHODS OF DIAGNOSING CANCER, ESPECIALLY LEUKEMIA AND LYMPHOMA | MCL1, BCL3, BCL9 | OR51E2 4615/4885CRBN 2599/4885FKBP5 3703/4885 |
| US-20140086833-A1 | NON-INVASIVE DIAGNOSTIC AGENTS AND METHODS OF DIAGNOSING INFECTIOUS DISEASE | MALT1, MAVS, BCL6 | OR51E2 2934/4885CRBN 3877/4885FKBP5 4003/4885 |
| US-20160287728-A1 | NON-INVASIVE DIAGNOSTIC AGENTS AND METHODS OF DIAGNOSING INFECTIOUS DISEASE | MALT1, MAVS, BCL6 | OR51E2 2934/4885CRBN 3877/4885FKBP5 4003/4885 |
| US-20180369430-A1 | METHOD OF DIAGNOSING AND/OR MONITORING THERAPY OF ATHEROSCLEROSIS | PCSK9, MMP12, LCLAT1 | OR51E2 3131/4885CRBN 2658/4885FKBP5 1559/4885 |
| US-20110117014-A1 | NON-INVASIVE DIAGNOSTIC AGENTS AND METHODS OF DIAGNOSING INFECTIOUS DISEASE | MALT1, BCL6, IRF3 | OR51E2 4147/4885CRBN 2813/4885FKBP5 3294/4885 |
| US-20070048216-A1 | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma | MCL1, BCL3, BCL9 | OR51E2 4615/4885CRBN 2599/4885FKBP5 3703/4885 |
| US-20160324993-A1 | NON-INVASIVE DIAGNOSTIC AGENTS OF CANCER AND METHODS OF DIAGNOSING CANCER, ESPECIALLY LEUKEMIA AND LYMPHOMA | MCL1, BCL3, BCL9 | OR51E2 4615/4885CRBN 2599/4885FKBP5 3703/4885 |
| US-20130216478-A1 | Non-Invasive Diagnostic Agents of Cancer and Methods of Diagnosing Cancer, Especially Leukemia and Lymphoma | MCL1, BCL3, BCL9 | OR51E2 4615/4885CRBN 2599/4885FKBP5 3703/4885 |
| US-10744214-B2 | Method of diagnosing and/or monitoring therapy of atherosclerosis | PCSK9, MMP12, LCLAT1 | OR51E2 3131/4885CRBN 2658/4885FKBP5 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.